[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479040":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer",null,"new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma",[13],"Diagnostic Test: TEG indices",{"label":15,"type":10,"description":16,"interventionNames":17},"Control","Patients undergoing major surgery",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","TEG indices","Blood samples",[9,15],[15],[26],{"name":27,"affiliation":5,"role":28},"Ana Gleisner, MD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Tracey MacDermott, BA BS CCRC","CONTACT","303-724-2757","tracey.macdermott@cuanschutz.edu",{"name":36,"role":32,"phone":10,"phoneExt":10,"email":37},"Ivan Rodriguez, MD","ivan.rodriguez@cuanschutz.edu",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"University of Colorado Denver","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-104.83192,39.72943,{"lat":51,"lon":50},[54,55,56],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},{"name":36,"role":32,"phone":10,"phoneExt":10,"email":37},{"name":57,"role":28,"phone":10,"phoneExt":10,"email":10},"Ana Fleisner, MD",{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[61],{"name":62,"class":63},"Haemonetics Corporation","INDUSTRY","100479040","pre--and-post-operative-teg-indices-in-patients-with-or-without-adenocarcinoma-undergoing-surgical-resection-100479040",false,"NCT05517811","Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection","Use of Viscoelastic Assays Beyond Coagulation: Pre- and Post-operative TEG","TEG","Inclusion Criteria:\n\n* new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study\n* 18 Years and older\n\nExclusion Criteria:\n\n* Under 18 years old\n* prisoners\n* those unable to provide informed consent\n* pregnant women\n* and those undergoing emergent or urgent operative intervention at the time of diagnosis",true,"ALL","18 Years","99 Years",{"count":77,"type":78},400,"ESTIMATED","OBSERVATIONAL","The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.",[82,83,84,85,15,86,87],"Liver Cancer","Esophageal Cancer","Colorectal Cancer","Lung Adenocarcinoma","Pancreas Cancer","Biliary Cancer","2025-01-27",{"date":90,"type":91},"2025-01-28","ACTUAL",{"date":93,"type":91},"2022-06-26",{"date":95,"type":78},"2028-07-31",{"name":5,"class":6},1]